clevidipine Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 674 167221-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clevidipine
  • clevelox
  • cleviprex
a calcium channel blocker and antihypertensive agent
  • Molecular weight: 456.32
  • Formula: C21H23Cl2NO6
  • CLOGP: 5.53
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 90.93
  • ALOGS: -5.23
  • ROTB: 10

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 1, 2008 FDA MEDICINES CO

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ventilation perfusion mismatch 138.78 127.35 15 169 74 4638734

Pharmacologic Action:

SourceCodeDescription
ATC C08CA16 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
FDA Chemical/Ingredient N0000007556 Dihydropyridines

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Tachyarrhythmia contraindication 6285003
Minimal change disease contraindication 44785005 DOID:10966
Low blood pressure contraindication 45007003
Pancreatitis contraindication 75694006 DOID:4989
Heart failure contraindication 84114007 DOID:6000
Hypertriglyceridemia contraindication 302870006
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.56 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
125MG/250ML (0.5MG/ML) CLEVIPREX CHIESI N022156 Nov. 8, 2013 DISCN EMULSION INTRAVENOUS 5856346 Jan. 5, 2021 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
25MG/50ML (0.5MG/ML) CLEVIPREX CHIESI N022156 Aug. 1, 2008 RX EMULSION INTRAVENOUS 5856346 Jan. 5, 2021 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
50MG/100ML (0.5MG/ML) CLEVIPREX CHIESI N022156 Aug. 1, 2008 RX EMULSION INTRAVENOUS 5856346 Jan. 5, 2021 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel BLOCKER WOMBAT-PK CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER WOMBAT-PK CHEMBL

External reference:

IDSource
4028719 VUID
N0000178415 NUI
C0766108 UMLSCUI
D08892 KEGG_DRUG
19O2GP3B7Q UNII
7490 INN_ID
439624003 SNOMEDCT_US
233603 RXNORM
d07312 MMSL
439471002 SNOMEDCT_US
4028719 VANDF
012824 NDDF
C118563 MESH_SUPPLEMENTAL_RECORD_UI
DB04920 DRUGBANK_ID
CHEBI:135738 CHEBI
7468 IUPHAR_LIGAND_ID
CHEMBL1237132 ChEMBL_ID
153994 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cleviprex HUMAN PRESCRIPTION DRUG LABEL 1 10122-610 EMULSION 0.50 mg INTRAVENOUS NDA 16 sections
Cleviprex HUMAN PRESCRIPTION DRUG LABEL 1 10122-611 EMULSION 0.50 mg INTRAVENOUS NDA 16 sections
Cleviprex HUMAN PRESCRIPTION DRUG LABEL 1 10122-612 EMULSION 0.50 mg INTRAVENOUS NDA 16 sections
Cleviprex HUMAN PRESCRIPTION DRUG LABEL 1 18124-011 EMULSION 0.50 mg INTRAVENOUS NDA 16 sections